Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: Two important unresolved questions

Bone Marrow Transplantation

Volumn 43, Issue 8, 2009, Pages 593-595

  Alegre, A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

APHERESIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CD34 SELECTION; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG MEGADOSE; EDITORIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKAPHERESIS; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE MYELOMA; OSTEOPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THERAPY DELAY; THROMBOCYTE COUNT;

ANTIGENS, CD34; CELL SEPARATION; CLINICAL TRIALS AS TOPIC; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 65449140288     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.371     Document Type: Editorial

References (20)

1. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D et al. Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); European Group for Blood and Marrow Transplantation EBMT (JACIE). The EBMT activity survey 2006 on hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 687-705.
2. Bjorkstrand B, Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: Past, present, and future. Semin Hematol 2007; 44: 227-233.
3. Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 7(Suppl 5): S207-S214.
4. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101-1114.
5. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
6. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
7. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
8. Marit G, Thiessard F, Faberes C, Cony-Makhoul P, Boiron JM, Bernard P et al. Factors affecting peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma: A monocentric study. Leukemia 1998; 12: 1447-1456.
9. Perea G, Sureda A, Martino R, Altés A, Martínez C, Cabezudo E et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001; 80: 592-597.
10. Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211-217.
11. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A et al. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocytecolony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 2007; 47: 2153-2160.
12. Jacoub JF, Suryadevara U, Pereyra V, Colón D, Fontelonga A, Mackintosh FR et al. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443-1450.
13. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
14. De la Rubia J, Bladé J, Lahueta JJ. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) study. Haematologica 2006; 91: 621-627.
15. Gertz M et al. Comparison of high-dose cyclophosphamide and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2008 (e-pub ahead of print).
16. Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J et al. Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic stem cell transplantation for myeloma? Bone Marrow Transplant 2008 (e-pub ahead of print, 6 October 2008; doi:10.1038/bmt.2008.322)
17. Maclean PS, Parker AN, McQuaker IG. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 2007; 40: 665-669.
18. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 795-798.
19. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 2008 (e-pub ahead of print, 25 August 2008).
20. DiPersio J, Stadtmauer E, Nademanee A. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs GCSF+ placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation (abstract). Blood 2007; 110: 445.